LARIMAR THERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
LARIMAR THERAPEUTICS, INC. (LRMR) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of -5.50% for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-05.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2020-03-05
- LARIMAR THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2019 was -5.50%.
- LARIMAR THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2018 was -5.10%.
- LARIMAR THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2017 was -1.50%.
- LARIMAR THERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2016 was -0.70%, a 177.78% decline from fiscal 2015.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month as first filed |
|---|---|---|
| 2019-12-31 | -5.50% 10-K · filed 2020-03-05 | |
| 2018-12-31 | -5.10% 10-K · filed 2020-03-05 | |
| 2017-12-31 | -1.50% 10-K · filed 2020-03-05 | 1.50% 10-K · filed 2018-03-09 |
| 2016-12-31 | -0.70% 10-K · filed 2019-03-14 | 0.70% 10-K · filed 2017-03-10 |
| 2015-12-31 | 0.90% 10-K · filed 2018-03-09 | |
| 2014-12-31 | 0.60% 10-K · filed 2017-03-10 | |
| 2013-12-31 | 0.60% 10-K · filed 2016-03-15 | |
| 2012-12-31 | 0.20% 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |